Observational studyPloS one2017
Decreasing Seroprevalence of Measles Antibodies after Vaccination - Possible Gap in Measles Protection in Adults in the Czech Republic.
Observational study in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- Seroprevalence of measles-specific IgG and genotype-specific neutralizing antibody responses in clinically confirmed cases during the 2021-2023 measles outbreaks in Liberia.Research square · 2026Article
- Measles - retrospective study of cases reported in a national notification system, Czech Republic, 2018-2024.BMC public health · 2026Article
- Measles Seroprevalence and Associated Factors among Adult Individuals in the City Center of Şanlıurfa Province.Sisli Etfal Hastanesi tip bulteni · 2026Article
- The Unprotected: Measles Seroprevalence in Children During the First Two Years of Life.Viruses · 2025Article
- Measles seroprevalence in Thailand: are adolescents and young adults at risk of measles?Singapore medical journal · 2024Article
- Measles Immunity Status of Greek Population after the Outbreak in 2017-2018: Results from a Seroprevalence National Survey.Vaccines · 2023Article
- SARS-CoV-2-The Role of Natural Immunity: A Narrative Review.Journal of clinical medicine · 2022Review
- Article
- Article
- Seroconversion rates following 2 doses of measles- mumps- rubella vaccination given at the ages 12 and 18 months: data for possible additional dose at older age.BMC immunology · 2022Article
- Seroprevalence of viral infectious diseases and associated factors in Korean patients with inflammatory bowel diseases.The Korean journal of internal medicine · 2022Article
- Seroepidemiology of Measles, Mumps, Rubella and Varicella in Italian Female School Workers: A Cross-Sectional Study.Vaccines · 2021Article
- Seroprevalence against the measles virus after vaccination or natural infection in an adult population in Madinah, Saudi Arabia.Human vaccines & immunotherapeutics · 2021Article
- Seroprevalence of Measles-, Mumps-, and Rubella-specific antibodies in the German adult population - cross-sectional analysis of the German Health Interview and Examination Survey for Adults (DEGS1).The Lancet regional health. Europe · 2021Article
- Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination.Vaccines · 2021Article
- Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran.BMC infectious diseases · 2021Article
- Seroprevalence to Measles Virus after Vaccination or Natural Infection in an Adult Population, in Italy.Vaccines · 2020Article
- Seroprevalence of IgG antibodies against measles in a selected Polish population - do we need to be re-vaccinated?Central-European journal of immunology · 2019Article
- Monitoring the age-specificity of measles transmissions during 2009-2016 in Southern China.PloS one · 2018Article
- Non-specific effects of vaccinations in high-income settings: How to address the issue?Human vaccines & immunotherapeutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIn recent years, Europe has recorded an increase in the number of measles outbreaks despite the implementation of vaccination into the National Immunization Programs. The Czech Republic introduced vaccination against measles into National Immunization Program in 1969. The aim of this study was to determine seroprevalence of IgG antibodies against measles in adults.
methodsOur study was designed as a prospective, multicenter cohort study. Samples of blood were taken from adults aged 18 years and over. Specific IgG antibodies were determined by ELISA method.
resultsA number of 1911 sera samples were obtained. The total seropositivity reached 83.3%, 14.3% of the results were negative and 2.4% were borderline. When comparing the individual age groups, the highest antibody seropositivity (> 96%) was detected in persons aged 50 years and over who were naturally infected in pre-vaccine era. The lowest seropositivity was recorded in the age groups 30-39 years (61.5%), 40-49 years (77.5%) and 18-29 years (81.1%).
conclusionsA long term high rate of seropositivity persists after natural measles infection. By contrast, it decreases over time after vaccination. Similarly, the concentrations of antibodies in persons with measles history persist for a longer time at a higher level than in vaccinated persons. Our results indicate possible gap in measles protection in adults born after implementation of vaccination into the National Immunization Programs. There are two probable reasons, decrease of measles antibody seropositivity in time after vaccination in setting of limited natural booster and one-dose vaccination schedule used in the first years after implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.